Nuvalent fetches $50m Series A
Nuvalent Inc, a creator of precisely targeted therapies for clinically proven kinase targets in cancer, has secured $50 million in Series A financing.
27 January 2021•1 min read
Nuvalent Inc, a creator of precisely targeted therapies for clinically proven kinase targets in cancer, has secured $50 million in Series A financing.
Download the November/December 2026 issue of Venture Capital Journal
2 November 2026 · 1 min read
Bites raises $40m Series A round to expand frontline worker learning platform
29 October 2026 · 7 mins read
OCIO Cerity seeks proof of exits as clients raise bar for venture funds
29 October 2026 · 4 mins read
Matter taps LPs that bring more than money for oversubscribed Fund II
28 October 2026 · 5 mins read
BackingMinds raises €50m for Fund III, focused on Nordic start-ups
26 October 2026 · 3 mins read
Singapore VC plants flag in Ohio in search of US investors
26 October 2026 · 6 mins read
New AI threats are fueling VC investment in cybersecurity
22 October 2026 · 4 mins read
